Merit

For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Growth Hormone Secretagogues

SS-31

Also known as: Elamipretide

SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) developed by Hazel Szeto (Cornell) and clinically advanced by Stealth BioTherapeutics. It concentrates in the inner mitochondrial membrane by binding cardiolipin. In September 2025, the FDA granted accelerated approval to elamipretide (brand name FORZINITY) as the first therapy for Barth syndrome — the first FDA-approved mitochondria-targeted drug. It remains investigational for other indications.

Real-time market data

Pricing for SS-31

Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.

Average price

$4.68/mg

range $0.00–$20.00/mg

Sellers

59

from $0.00

45-day trend

+5.5%

vs 45-day avg $/mg

51 of 59 sellers have a current price· 22 stale listings hidden (not seen in 7 days)

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Independent evidence

COAs for SS-31

117 third-party tests across 21 vendors. Each card links to the full report.

All 117 COAs for SS-31 →
Measured purity 98.6%–100.0% across 66 COAs
Measured purity over time
✓ Vendor-published
99.91 %
Jun 2026
Freedom Diagnostics Moderate

For

SS-31

by Ion Peptide· batch 2510-06242026

COA on file
Aggregated · 3rd-party listing
99.91 %
Jun 2026
Freedom Diagnostics Moderate

For

SS-31

by Ion Peptide· batch 2S10-06242026

✓ Vendor-published
99.19 %
May 2026
Kovera Labs

For

SS-31

by Reta One Labs· batch SS100626

COA on file
Aggregated · 3rd-party listing
99.88 %
May 2026
ILS Labs Strong

For

S-31

by Ion Peptide· batch SS3150-05042026

Aggregated · 3rd-party listing
99.87 %
May 2026
ILS Labs Strong

For

S-31

by Ion Peptide· batch SS3150-05042026

Aggregated · 3rd-party listing
99.64 %
May 2026
ILS Labs Strong

For

SS-31

by Ion Peptide· batch 2S10-05042026

Aggregated · 3rd-party listing
99.64 %
May 2026
ILS Labs Strong

For

S-31

by Ion Peptide· batch 2S10-05042026

Aggregated · 3rd-party listing
99.73 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

SS-31

by Peptidegurus· batch cmojgr89m002r9grxu1x2sttx

Aggregated · 3rd-party listing
99.86 %
Apr 2026
Freedom Diagnostics Moderate · HPLC

For

SS-31

by Peptide Plugs· batch 121-A-D

✓ Vendor-published
99.83 %
Apr 2026
TrustPointe Analytics Moderate

For

SS-31

by Peptide Partners· batch SPL-3436

COA on file
Aggregated · 3rd-party listing
99.94 %
Mar 2026
Kovera Labs

For

§-31

by Ion Peptide· batch §-3110-03242026

Aggregated · 3rd-party listing
99.94 %
Mar 2026
Kovera Labs

For

§-31

by Ion Peptide· batch §-3150-03232026

Aggregated · 3rd-party listing
99.94 %
Mar 2026
Freedom Diagnostics Moderate · HPLC

For

SS-31

by Forge Performance Co.· batch Blue Top

Aggregated · 3rd-party listing
99.76 %
Mar 2026
Janoshik Analytical Limited · HPLC

For

SS-31

by Qihang Peptide· batch 3

Aggregated · 3rd-party listing
99.97 %
Mar 2026
Kovera Labs · HPLC

For

SS-31

by Glacier Aminos· batch MTP10GA-03

Aggregated · 3rd-party listing
99.04 %
Mar 2026
Vanguard Laboratory Strong · HPLC

For

SS-31

by Mile High Compounds· batch SS3-010-MH-04

✓ Vendor-published
99.82 %
Mar 2026
Freedom Diagnostics Moderate

For

SS-31

by Ion Peptide· batch C3150-02272026

COA on file
Aggregated · 3rd-party listing
99.81 %
Feb 2026
Freedom Diagnostics Moderate

For

SS-31

by Orbitrex Peptides· batch MTP100326

Aggregated · 3rd-party listing
99.75 %
Feb 2026
Janoshik Analytical Limited · HPLC

For

SS-31

by Qihang Peptide· batch 2

Aggregated · 3rd-party listing
99.69 %
Feb 2026
Freedom Diagnostics Moderate · HPLC

For

SS-31

by Peptide Supply Co.· batch PSCSS3150001

Aggregated · 3rd-party listing
99.68 %
Feb 2026
Chromate Moderate · HPLC

For

SS-31

by Peptide Partners· batch SS202602

✓ Vendor-published
99.69 %
Feb 2026
Chromate Moderate

For

SS-31

by Peptide Partners· batch SS202602

COA on file
✓ Vendor-published
99.96 %
Feb 2026
Freedom Diagnostics Moderate

For

SS-31

by Ion Peptide· batch SS3110-02032026

COA on file
Aggregated · 3rd-party listing
99.80 %
Feb 2026
Vanguard Laboratory Strong

For

SS-31

by Licensed Peptides· batch LP02202016

Research depth

14 citations indexed for SS-31

All research on SS-31 →

Study · 2026

Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence

Exposure to ionizing radiation, such as from radiation therapy or accidental radiation exposure can have adverse effects on the heart. While radiation injury in the heart may include cardiomyocyte senescence, there are no available strategies to prevent this phenomenon.

in-vitro · 2026

Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced Cardiomyoblast H9C2 Cell Senescence

Doxorubicin (DOX), an effective chemotherapeutic agent for many types of cancer, is known for significant cardiotoxic side effects, which largely limit its clinical usage.

animal · 2026

Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model

Background Exercise intolerance, promoted by skeletal muscle- and mitochondrial dysfunction, has been identified as a therapeutic target in heart failure with preserved ejection fraction (HFpEF).

Study · 2026

Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function

Membrane binding and aggregation properties of α-synuclein are closely associated with Parkinson's disease and a class of related syndromes named as synucleinopathy.

animal · 2026

Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice

Ischemic stroke is a severe cerebrovascular disorder characterized by a cascade of pathological processes, including neuroinflammation and apoptosis. These processes lead to high mortality rates and long-term disabilities, imposing substantial socioeconomic burdens.

animal · 2026

Elamipretide (SS-31) promotes recovery by preserving mitochondrial bioenergetics and neural remodeling after spinal cord injury

Spinal cord injury (SCI) induces secondary damage characterized by mitochondrial dysfunction, oxidative stress, and apoptosis, which collectively impede neurological recovery. Elamipretide (SS-31) is a mitochondria-targeting peptide with potential neuroprotective effects.